MiR-3960 inhibits bladder cancer progression via targeting of DEXI
Quick Facts
- Publication title: MiR-3960 inhibits bladder cancer progression via targeting of DEXI
- Journal: BIOCHEM BIOPH RES CO
- Year: 2023
- DOI: 10.1016/j.bbrc.2023.05.055
- PMID/PMCID: 37230046
Research overview
MicroRNAs (miRNAs) are dominant cargo in exosomes and act as master regulators of cell function, inhibiting mRNA translation and affecting gene silencing. Our results demonstrate the potential role of miR-3960-mediated inhibition of DEXI as a therapeutic strategy against BC.
Key findings
The results showed that miR-3960 levels in BC tissue were positively correlated with patient survival time.
Dexi was a major target of miR-3960.
Dexi knockout inhibited MB49 cell proliferation and promoted cisplatin- and gemcitabine-induced apoptosis.
Transfection of miR-3960 mimic inhibited DEXI expression and organoid growth.
Study design
A microarray was used to identify miRNAs in mouse bladder carcinoma cell line MB49 exosomes.
Real-time reverse transcription polymerase chain reaction was used to examine the expression of miRNAs in BC and healthy donor serum.
Western blotting and immunohistochemical staining were used to examine the expression of dexamethasone-induced protein (DEXI) in patients with BC.
Echo Biotech Role
Echo Biotech contributed cargo loading; the study also used or cited ExoLoad®.
Related platforms: Echosome®, Research Reagents & Tools
Related services and capabilities: Small RNA / Cargo Loading, Research Reagent / Product Supply
Related products or reagents: ExoLoad® Nucleic Acid Loading Kit
References
Original publication: MiR-3960 inhibits bladder cancer progression via targeting of DEXI Biochemical and biophysical research communications. 2023. DOI: 10.1016/j.bbrc.2023.05.055. PMID/PMCID: 37230046.